Enveric Biosciences, Inc. (NasdaqCM: ENVB)
Health Care · Pharmaceuticals · US
$1.42
-0.70% today · -91.0% 1Y
Enveric Biosciences, Inc. (NasdaqCM: ENVB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.40M and employs 6 people.
Over the last twelve months the share price has lost 91.0%, trading between 1.25 and 17.64.
Tweenvest scores Enveric Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ENVB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.40M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -7.48
- Dividend yield
- —
- Beta (5Y)
- 1.11
- 52-week high
- $17.64
- 52-week low
- $1.25
- Avg volume (3M)
- —
- Shares outstanding
- 4.48M
- Employees
- 6
- Next earnings
- —
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
- Listed since
- May 4, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.16 | +0.34% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.18 | -0.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.23% |
Figures last refreshed Aug 18, 2026.